Sign in
CompletedPhase 4

Maternal Fatigue After Postpartum Anemia Treatment With Intravenous Ferric Carboxymaltose and Oral Iron Therapy

Key facts

Who runs it
Pakistan Air Force (PAF) Hospital Islamabad
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
134 people enrolled
Started
20 Apr 2026
Ended
20 Sept 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • INTRAVENOUS FERRIC CARBOXYMALTOSE
  • oral iron therapy
Record updated
19 October 2026

Who can take part

Age
18 years to 40 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Women aged 18-45 years
  • Postpartum period (within 48 hours)
  • Hemoglobin < 10 g/dL
  • Singleton delivery
  • Willing to participate Exclusion Criteria
  • Severe anemia requiring blood transfusion
  • Known hemoglobinopathies
  • Chronic medical illness (renal, hepatic, cardiac)
  • Postpartum sepsis or PPH
  • Previous iron therapy in current pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Postpartum Anemia is common after childbirth and may contribute to tiredness and reduced wellbeing in mothers.This randomized controlled trial will compare two treatments for postpartum iron deficiency:intravenous ferric carboxymaltose and oral iron therapy .This study will assess whether intravenous ferric carboxymaltose provides greater improvement in maternal fatigue during the first 6 weeks after childbirth compared to oral iron.Secondary outcomes will be assessment of depressive symptoms and breastfeeding self efficacy .Eligible postpartum women with iron deficiency anemia will be randomly assigned to receive either intravenous ferric carboxymaltose or oral iron therapy and will be followed for six weeks.The study hypothesis is that intravenous ferric carboxymaltose will result in greater improvement in maternalfatigue and may also effect breastfeeding self efficacy .

The 2 groups in the trial

  • INTRAVENOUS FERRIC CARBOXYMALTOSE groupTreatment being tested

    single dose Intravenous ferric carboxymaltose administered postpartum

    Treatment: INTRAVENOUS FERRIC CARBOXYMALTOSE

  • oral iron therapy groupExisting treatment, for comparison

    oral iron therapy to treat anemia as comparative group

    Treatment: oral iron therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Maternal Fatigue After Postpartum Anemia Treatment With Intravenous Ferric Carboxymaltose Versus Oral Iron Therapy
Record updated
19 October 2026